AKT1 and cancer: In conclusion, Naringin mainly inhibits the signaling pathways such as Akt/NF-κB by down-regulating the expression of drug resistance gene MDR mRNA and related proteins P-gp and MRP, thus reversing the resistance of tumor cells to chemotherapeutic drugs, and its combination with chemotherapeutic drugs can significantly enhance the sensitivity of cancer cells to the drugs.